Clinical scenarios of suboptimal response to rituximab in relapsing ANCA-associated vasculitis. (PubMed, Front Med (Lausanne)) - Sep 20, 2026 - "In this exploratory and hypothesis-generating analysis, a small subset of patients with relapsing AAV showed suboptimal outcomes with rituximab. Residual disease activity at month 4, particularly in patients with PR3-ANCA positivity and ENT involvement, may represent a clinical subgroup associated with an increased frequency of earlier relapse, although this observation requires confirmation."
Journal • ANCA Vasculitis • Rare Diseases • Vasculitis
|
|
; David R W Jayne; Ellen Romich; Peter A Merkel; Rona M Smith; Sergio Prieto-González
|